Clinical trials: Major Adverse Cardiac Events
Coronary Heart Disease
SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)
The overall objective of this integrated analysis is to evaluate the clinical safety and efficacy of long-term treatment with darapladib enteric coated tablets, 160mg, as compared to placebo when added to standard of care in…
- Trial name
- NCT01636271
- Testing
- darapladib
- Volunteers
- 28,855 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease, DES
A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial
We hypothesized that clopidogrel mono-therapy will not be inferior to the extended DAPT in terms of the occurrence of both ischemic and bleeding events, for lesions or patients at high risk for either ischemic or bleeding…
- Trial name
- NCT03947229
- Testing
- Clopidogrel mono-therapy, Dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,200 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Plaque
PCCT-Defined High-Risk Plaque and Future Coronary Events: The PREDICT Study
This prospective cohort study aims to determine whether high-risk coronary plaques identified by novel Photon-Counting Detector CT (PCCT) independently predict future major adverse cardiovascular events (MACE).
- Conditions
- Coronary Artery Disease, Plaque, Photon-Counting Computed Tomography
- Trial name
- PREDICT (NCT07822737)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Chao Yang Hospital
Physical Activity, Coronary Artery Disease
Prognostic Impact of Physical Activity Patterns After Percutaneous Coronary Intervention (PIPAP Study)
Physical activity monitoring after coronary bypass grafting and other major surgeries has been found to be predictive for hospital readmission and adverse outcome.
- Trial name
- PIPAP (NCT04663373)
- Testing
- Step counting
- Where
- Switzerland
- Volunteers
- 568 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Incidence of Major Adverse Cardiac Events
Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy
To compare the incidence of major adverse cardiac events among a series of patients receiving the Synergy drug-eluting stent with bioabsorbable polymer to historical controls who have received the Promus Premier drug-eluting…
- Trial name
- NCT02823730
- Testing
- PCI with Synergy Stent
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Medstar Health Research Institute
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for…
- Trial name
- NCT05487560
- Testing
- Esomezol Cap
- Where
- South Korea
- Volunteers
- 4,133 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Atherosclerosis
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
- Trial name
- STABILITY (NCT00799903)
- Testing
- Darapladib
- Where
- 650 sites in United States, Argentina and 37 more
- Volunteers
- 15,828 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease, In-stent Restenosis
CT-FFR-guided Strategy for In-stent Restenosis
This study will be a prospective, randomized clinical trial to compare standard practice guided by usual care testing to CT-FFR-guided management in patients with in-stent restenosis.
- Trial name
- NCT05611190
- Testing
- CT-FFR, Usual Care
- Volunteers
- 294 people
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline